» Articles » PMID: 35474707

Substance Use Disorder is Associated with Alcohol-associated Liver Disease in Patients with Alcohol Use Disorder

Overview
Journal Gastro Hep Adv
Specialty Gastroenterology
Date 2022 Apr 27
PMID 35474707
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Substance use disorder (SUD) commonly associates with alcohol use disorder (AUD), and certain substances have independently been shown to drive liver injury. In this work, we sought to determine if co-existing SUD in patients with AUD associated with the presence of alcohol-associated liver disease (ALD).

Methods: We performed a cross-sectional analysis using the Mass General Brigham Biobank to identify patients based on ICD-10 codes. We performed multivariate analyses accounting for a wide range of demographic and clinical variables to evaluate the association between SUD and ALD. We subsequently used the same method to evaluate the association between SUD and hepatic decompensation.

Results: We identified 2848 patients with a diagnosis of AUD, 9.0% of which had ALD. 25.2% had a history of SUD. In multivariate analyses, patients with SUD were more frequently diagnosed with ALD compared to those without SUD (OR = 1.95, P = 0.001). Furthermore, the number of concurrent SUDs was positively associated with the diagnosis of ALD (OR: 1.33, P < 0.001). Independent of the presence of other SUDs, opioid use disorder in patients with AUD was associated with ALD (OR = 1.902, P = 0.02). In subsequent analyses, we found that sedative use disorder was associated with hepatic decompensation (OR: 2.068, P = 0.03).

Conclusions: In patients with AUD, SUD, and in particular opioid use disorder, was independently associated with the diagnosis of ALD.

Citing Articles

Advances in the management of alcohol-associated liver disease.

Anouti A, Kerr T, Mitchell M, Cotter T Gastroenterol Rep (Oxf). 2024; 12:goae097.

PMID: 39502523 PMC: 11537353. DOI: 10.1093/gastro/goae097.


Survival and Disease Progression in Older Adult Patients With Cirrhosis: A Retrospective Study.

Al-Smadi K, Qureshi A, Buitrago M, Ashouri B, Kayali Z Int J Hepatol. 2024; 2024:5852680.

PMID: 39149542 PMC: 11326880. DOI: 10.1155/2024/5852680.


Effects of Marine Natural Products on Liver Diseases.

Sun Y, Dong Y, Cui X, Guo X, Zhang J, Yu C Mar Drugs. 2024; 22(7).

PMID: 39057397 PMC: 11278422. DOI: 10.3390/md22070288.


Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder.

Haque L, Leggio L Hepatology. 2024; 80(6):1408-1423.

PMID: 38935926 PMC: 11841743. DOI: 10.1097/HEP.0000000000000996.

References
1.
Verna E, Schluger A, Brown Jr R . Opioid epidemic and liver disease. JHEP Rep. 2020; 1(3):240-255. PMC: 7001546. DOI: 10.1016/j.jhepr.2019.06.006. View

2.
Gainer V, Cagan A, Castro V, Duey S, Ghosh B, Goodson A . The Biobank Portal for Partners Personalized Medicine: A Query Tool for Working with Consented Biobank Samples, Genotypes, and Phenotypes Using i2b2. J Pers Med. 2016; 6(1). PMC: 4810390. DOI: 10.3390/jpm6010011. View

3.
Saha T, Grant B, Chou S, Kerridge B, Pickering R, Ruan W . Concurrent use of alcohol with other drugs and DSM-5 alcohol use disorder comorbid with other drug use disorders: Sociodemographic characteristics, severity, and psychopathology. Drug Alcohol Depend. 2018; 187:261-269. DOI: 10.1016/j.drugalcdep.2018.03.006. View

4.
Atici S, Cinel I, Cinel L, Doruk N, Eskandari G, Oral U . Liver and kidney toxicity in chronic use of opioids: an experimental long term treatment model. J Biosci. 2005; 30(2):245-52. DOI: 10.1007/BF02703705. View

5.
Vitcheva V . Cocaine toxicity and hepatic oxidative stress. Curr Med Chem. 2012; 19(33):5677-82. DOI: 10.2174/092986712803988929. View